Sulindac sulfone induces a decrease of β-catenin in HNSCC

Anticancer Research

Volumn 30, Issue 2, 2010, Pages 339-343

  Sauter, Alexander ^a   Soulsby, Hannah ^b   Hormann, Karl ^a   Naim, Ramin ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

catenin; Apoptosis; Cell culture; Cell line; HNSCC; Sulindac sulfone; UM SCC

Indexed keywords

BETA CATENIN; SULINDAC SULFONE;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BETA CATENIN; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; SULINDAC; TUMOR CELLS, CULTURED;

EID: 77950530336     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Loeb LA: Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51(12): 3075-3079, 1991.
2. Aberle H, Schwartz H and Kemler R: Cadherin-catenin complex: protein interactions and their implications for Cadherin function. J Cell Biochem 61(4): 514-523, 1996.
3. Rubinfeld B, Robbins P, El Gamil M, Albert I, Porfiri E and Polakis P: Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275(5307): 1790-1792, 1997.
4. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R and Ben Ze'ev A: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96(10): 5522-5527, 1999.
5. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science 281(5382): 1509-1512, 1998.
6. Polakis P, Hart M and Rubinfeld B: Defects in the regulation of beta-catenin in colorectal cancer Adv Exp Med Biol pp. 47023-47032, 1999.
7. Aberle H, Bauer A, Stappert J, Kispert A and Kemler R: Beta-catenin is a target for the ubiquitin-proteasome pathway EMBO J 16(13): 3797-3804, 1997.
8. Herren B, Levkau B, Raines EW and Ross R: Cleavage of beta-catenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases. Mol Biol Cell 9(6): 1589-1601, 1998.
9. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R and Ahnen DJ: Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 57(12): 2452-2459, 1997.
10. Goluboff ET: Exisulind, a selective apoptotic antineoplastic drug. Expert Opin Investig Drugs 10(10): 1875-1882, 2001.
11. Grenman R, Burk D, Virolainen E, Buick RN, Church J, Schwartz DR and Carey TE: Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer 44(1): 131-136, 1989.
12. Lim JT, Piazza GA, Han EK, Delohery TM, Li H, Finn TS, Buttyan R, Yamamoto H, Sperl GJ, Brendel K, Gross PH, Pamukcu R and Weinstein IB: Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 58(7): 1097-1107, 1999.
13. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr and Chou TC: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59(24): 6178-6184, 1999.
14. Han EK, Arber N, Yamamoto H, Lim JT, Delohery T, Pamukcu R, Piazza GA, Xing WQ and Weinstein IB: Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat 48(3): 195-203, 1998
15. Rahman MA, Dhar DK, Masunaga R, Yamanoi A, Kohno H and Nagasue N: Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res 60(8): 2085-2089, 2000.
16. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M and Gallo O: Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of me head and neck. Cancer 95(9): 1902-1910, 2002.
17. Wijnhoven BP, Dinjens WN and Pignatelli M: E-Cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 87(8): 992-1005, 2000.
18. Lopez-Gonzalez JS, Cristerna-Sanchez L, Vazquez-Manriquez ME, Jimenez-Orci G and Aguilar-Cazares D: Localization and level of expression of beta-catenin in human laryngeal squamous cell carcinoma. Otolaryngol Head Neck Surg 130(1): 89-93, 2004
19. Hirvikoski P, Kumpulainen EJ, Virtaniemi JA, Helin HJ, Rantala I, Johansson RT, Juhola M and Kosma VM: Cytoplasmic accumulation of alpha-catenin is associated with aggressive features in laryngeal squamous-cell carcinoma. Int J Cancer 79(5): 546-550, 1998.
20. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R and Birchmeier W: Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382(6592): 638-642, 1996.
21. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D and Pamukcu R: Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 60(13): 3338-3342, 2000.
22. Fukuda K: Apoptosis-associated cleavage of beta-catenin in human colon cancer and rat hepatoma cells. Int J Biochem Cell Biol 31(3-4): 519-529, 1999.
23. Davies NM and Watson MS: Clinical pharmacokinetics of sulindac. A dynamic old drug. Clin Pharmacokinet 32(6): 437-459, 1997.